Jeffery R. Sawyer

Professor

UAMS

Also affiliated: Arkansas Children's Hospital (1994–2008); Harvard University (2005); Union University (2008); Harvard University Press (2005); Campbell Clinic (2008–2018); Winthrop Rockefeller Foundation (2023); University of Minnesota Medical Center (2008); Erasmus MC Cancer Institute (2019); Le Bonheur Children's Hospital (2017–2018); University of Oklahoma Health Sciences Center (2005); University of Tennessee at Knoxville (2015–2017)

Faculty Researcher

Pathology, College of Medicine

10 h-index 55 pubs 674 cited

Research Areas

Biomedical Subjects

Links

Lab Website UAMS TRI Profile

OverviewAI-generated summary

Jeffery R. Sawyer's research focuses on the cytogenetic and molecular underpinnings of multiple myeloma, a cancer of plasma cells. His work investigates how specific chromosomal abnormalities, such as the deletion of chromosome 1p13.3 and the amplification or gain of chromosome 1q21, correlate with patient outcomes. He has published findings demonstrating that the concomitant presence of these two alterations is associated with a poorer prognosis in multiple myeloma patients, utilizing fluorescence in situ hybridization (FISH) for detection. Additionally, Sawyer's research has explored the role of phenotypic markers identified through eight-color flow cytometry in predicting disease progression in monoclonal gammopathy of unknown significance, a precursor condition to multiple myeloma. His scholarship metrics include an h-index of 10 and 55 total publications, with 670 citations.

Metrics

h-index: 10
Publications: 55
Citations: 674

Selected Publications

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes (2024)

Blood DOI OpenAlex
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023)

Cancer 9 citations DOI OpenAlex
Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome (2021)

Blood DOI OpenAlex
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)

Blood 1 citation DOI OpenAlex
Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups (2019)

Blood 2 citations DOI OpenAlex
The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells (2019)

Blood DOI OpenAlex
EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab (2019)

Blood 6 citations DOI OpenAlex
An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome (2018)

Blood 8 citations DOI OpenAlex
Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53 (2018)

Blood 3 citations DOI OpenAlex
Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma (2017)

Blood DOI OpenAlex
Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status (2017)

Blood DOI OpenAlex
Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC (2016)

Blood 2 citations DOI OpenAlex
Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression (2016)

Blood 2 citations DOI OpenAlex
Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma (2015)

Blood DOI OpenAlex
A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant (2015)

Blood 2 citations DOI OpenAlex